Derek Galligan, Staci Williamson, Jessie Myers, Andy I Chen, Brandon Hayes-Lattin, Craig Okada, Stephen Spurgeon, Richard Maziarz, Levanto Schachter
BACKGROUND: Peripheral T-cell lymphomas (PTCL) are a group of aggressive malignancies with inferior outcomes compared to B-cell non-Hodgkin lymphoma (NHL). Both allogeneic and autologous hematopoietic cell transplantation (HCT) are commonly employed for consolidation and salvage. MATERIALS AND METHODS: We conducted a single-center review of all adult PTCL patients at OHSU who received HCT from 1991 to 2020 with responses assed by CIBMTR criteria. RESULTS: 88 patients (autoHCT = 52, alloHCT = 36) were identified from the internal registry of ∼3800 autoHCT & alloHCT recipients in that time period...
September 12, 2023: Clinical Lymphoma, Myeloma & Leukemia
Michael Slade, Mark A Fiala, Marie Kirchmeyer, Jeff King, Feng Gao, Mark A Schroeder, A Keith Stewart, Keith Stockerl-Goldstein, Christine Chen, Ravi Vij
BACKGROUND: Second autologous hematopoietic cell transplant (AHCT2) is a useful therapeutic modality for fit patients with multiple myeloma who have a durable remission after upfront autologous hematopoietic cell transplant. Retrospective studies have suggested a significant benefit of incorporating maintenance therapy post-AHCT2, but prospective data regarding specific regimens is lacking. OBJECTIVE(S): The purpose of this study was to investigate the use of elotuzumab, pomalidomide and dexamethasone (EPd) as salvage therapy prior to and maintenance after AHCT2 for relapsed multiple myeloma...
September 21, 2023: Transplantation and cellular therapy
Mohamed Badawi, Sheryl Coppola, Doerthe Eckert, Sathej Gopalakrishnan, Benjamin Engelhardt, Eva Doelger, Weize Huang, Edyta Dobkowska, Shaji Kumar, Rajeev M Menon, Ahmed Hamed Salem
Venetoclax, a potent BCL-2 inhibitor, is currently under development for treatment of t(11;14) Multiple myeloma (MM). The objective of this research was to investigate the exposure-response relationships of venetoclax for a phase 1/2 study evaluating venetoclax monotherapy or in combination with dexamethasone in relapsed or refractory MM. A total of 117 patients receiving venetoclax at 300, 600, 800, 900, or 1200 mg were included in the analysis. The impact of venetoclax exposures on efficacy (objective response rate [ORR], progression-free survival [PFS] and overall survival [OS]) as well as safety (treatment-emergent adverse effects (grade ≥3) of neutropenia, infection, and any grade of serious treatment-emergent adverse effects) was evaluated...
September 23, 2023: Hematological Oncology
Weronika Lebowa, Jacek Prusak, Marlena Leśniak, Jakub Wasiewicz, Artur Jurczyszyn
INTRODUCTION: The majority of patients with advanced neoplasms have religious/spiritual needs, and for most of them religion and/or spirituality is important. The psychology of religion and spirituality is one the forms of support offered to patients with advanced cancer. R/S are factors which impact health-related quality of life (HRQoL). The aim of this paper was to assess the influence of R/S on the HRQoL of patients diagnosed with MM. MATERIALS AND METHODS: The patients filled out anonymous questionnaires about R/S and the HRQoL scale...
August 20, 2023: Clinical Lymphoma, Myeloma & Leukemia
Cristian Maximiliano Seehaus, Natalia Schutz, Erika Brulc, Gonzalo Ferini, Jorge Arbelbide, Dorotea Fantl, Ana Lisa Basquiera
INTRODUCTION: The treatment of elderly multiple myeloma (MM) patients with autologous stem cell transplantation (ASCT) is a controversial procedure. Most clinical trials evaluating the safety and efficacy of ASCT have primarily included patients younger than 65 years. DESIGN AND METHODS: This was a retrospective analysis of patients with MM who underwent ASCT between 2008 and 2018. Patients at or over 65 years were compared with patients under 65 years. We analyzed treatment-related mortality (TRM), response rate, progression-free survival (PFS) and overall survival (OS)...
September 5, 2023: Hematology, Transfusion and Cell Therapy
Gemma K Reynolds, Beatrice Sim, Tim Spelman, Ashmitha Thomas, Anthony Longhitano, Mary Ann Anderson, Karin Thursky, Monica Slavin, Benjamin W Teh
A registered (PROSPERO - CRD42022346462) systematic review and meta-analysis was conducted of all-grade infections amongst adult patients receiving CAR-T therapy for haematological malignancy. Meta-analysis of pooled incidence, using random effects model, was conducted. Cochran's Q test examined heterogeneity. 2678 patients across 33 studies were included in the primary outcome. Forty-percent of patients (95% CI: 0.33 - 0.48) experienced an infection of any grade. Twenty-five percent of infection events (95% CI: 0...
September 20, 2023: Critical Reviews in Oncology/hematology
Ala Aloui, Mohamed Samih Kacem, Sami Bahroun, Ali Jhimi, Anis Bouaziz, Mohamed Samir Daghfous
INTRODUCTION AND IMPORTANCE: Solitary spinal plasmacytoma (SSP) is an uncommon neoplasm originating from bone marrow plasma cells. Although infrequent in the thoracic region, it has the potential to induce substantial damage. In this study, we present the case of a patient with thoracic spine SSP treated through surgical intervention. CASE PRESENTATION: We report the case of a 38-year-old female who presented with progressive mid-back pain, numbness, weakness in both lower limbs and gait disturbance...
September 14, 2023: International Journal of Surgery Case Reports
Tatsuya Konishi, Toshiki Ochi, Masaki Maruta, Kazushi Tanimoto, Yukihiro Miyazaki, Chika Iwamoto, Takashi Saitou, Takeshi Imamura, Masaki Yasukawa, Katsuto Takenaka
Immunotherapy using bispecific antibodies including bispecific T-cell engager (BiTE) has the potential to enhance the efficacy of treatment for relapsed/refractory multiple myeloma. However, myeloma may still recur after treatment due to downregulation of a target antigen and/or myeloma cell heterogeneity. To strengthen immunotherapy for myeloma while overcoming its characteristics, we have newly developed a BiTE-based modality, referred to as Bridging-BiTE (B-BiTE). B-BiTE was able to bind to both a human IgG-Fc domain and the CD3 molecule...
September 22, 2023: Blood
Paul P Liu, Lea Cunningham, Matthew Douglas Merguerian, Katherine R Calvo, Joie Davis, Natalie T Deuitch, Alina E Dulau-Florea, Nisha Patel, Kai Yu, Keith Sacco, Sumona Bhattacharya, Monica Passi, Neval Ozkaya, Seila Vanessa De Leon, Shawn Nathan Chong, Kathleen Marie Craft, Jamie L Diemer, Erica Bresciani, Kevin J O'Brien, Elizabeth J Andrews, Nguyen Park, Londa Hathaway, Edward W Cowen, Theo Heller, Kerry Ryan, Amisha Barochia, Khanh Nghiem, Julie E Niemela, Sergio D Rosenzweig, David J Young, Pamela Frischmeyer-Guerrerio, Raul C Braylan
Deleterious germline RUNX1 variants cause the autosomal dominant disease familial platelet disorder with associated myeloid malignancy (FPDMM), characterized by thrombocytopenia, platelet functional defects and predisposition to hematologic malignancies (HMs). We launched a FPDMM natural history study and, from January 2019-December 2021, enrolled 214 participants, including 111 patients with 39 different RUNX1 variants from 45 unrelated families. Of those with available data, 91% (70/77) had thrombocytopenia, 100% (18/18) had abnormal platelet aggregometry, 46% (16/35) had platelets with decreased dense granules, and 51% (28/55) had abnormal bleeding scores...
September 22, 2023: Blood
Ehsan Malek, Gi-Ming Wang, Curtis Tatsuoka, Jennifer Cullen, Anant Madabhushi, James J Driscoll
PURPOSE: The gold standard for monitoring response status in patients with multiple myeloma (MM) is serum and urine protein electrophoresis which quantify M-spike proteins; however, the turnaround time for results is 3-7 days which delays treatment decisions. We hypothesized that machine learning (ML) could integrate readily available clinical and laboratory data to rapidly and accurately predict patient M-spike values. METHODS: A retrospective chart review was performed using the deidentified, electronic medical records of 171 patients with MM...
September 2023: JCO Clinical Cancer Informatics
Mei-Tsen Chen, Shih-Tsung Huang, Huai-Hsuan Huang, Wen-Jone Chen, Bor-Sheng Ko, Fei-Yuan Hsiao
Although novel agents for multiple myeloma (MM) have a better response rate and survival in both newly diagnosed and relapsed/refractory MM patients, concerns regarding the association between MM treatments and thromboembolic events have been raised. The aim of this population-based study was to examine the association between different combinations of MM treatments and the risk of thromboembolic events. We conducted a nested case-control study using the Taiwan Cancer Registry (TCR) and National Health Insurance Research Database (NHIRD)...
September 22, 2023: Journal of Thrombosis and Thrombolysis
Teresa Meenaghan, Amjad Hayat, Geraldine Walpole, Maura Dowling
Myeloma is an aggressive B-cell malignancy resulting from an uncontrolled production of plasma cells in the bone marrow. A multitude of drugs and combinations of drugs are now approved for use to treat this complex disease and nurses require knowledge and skills in recognising and managing new side effects associated with these treatments. This article presents an overview of some of the newer and recently approved drugs and the important side effects that have been associated with them. Clinical nurse specialists and advanced nurse practitioners are at the forefront of patients' treatment journeys and play a central role in supporting patients and families to manage side effects...
September 21, 2023: British Journal of Nursing: BJN
Wen Yu, De-Dong Cao, Qiu-Bai Li, Hui-Ling Mei, Yu Hu, Tao Guo
No abstract text is available yet for this article.
September 22, 2023: Oncotarget
Madhav V Dhodapkar
Immune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 000.
September 22, 2023: Clinical Cancer Research
Marta Dratwa, Piotr Łacina, Aleksandra Butrym, Diana Porzuczek, Grzegorz Mazur, Katarzyna Bogunia-Kubik
Telomere dysfunction is a notable event observed in many cancers contributing to their genomic instability. A major factor controlling telomere stability is the human telomerase reverse transcriptase catalytic subunit (hTERT). Telomere shortening has been observed in multiple myeloma (MM), a plasma cell malignancy with a complex and heterogeneous genetic background. In the present study, we aimed to analyse telomere length and hTERT genetic variants as potential markers of risk and survival in 251 MM patients...
September 22, 2023: Scientific Reports
Abdulfatah M Alayoubi, Zakaria Y Khawaji, Mohammed A Mohammed, François E Mercier
Gene therapy represents a significant potential to revolutionize the field of hematology with applications in correcting genetic mutations, generating cell lines and animal models, and improving the feasibility and efficacy of cancer immunotherapy. Compared to different genetic engineering tools, clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR-associated protein 9 (Cas9) emerged as an effective and versatile genetic editor with the ability to precisely modify the genome. The applications of genetic engineering in various hematological disorders have shown encouraging results...
September 22, 2023: Annals of Hematology
Ghazi H Mogharbel, Ahmad S Badawi, Amal Yaseen Zaman, Mehrevan M Abd Elmoniem, Ibrahim M Abdel-Rahman, Mariam Eid Alenazi, Fareed Akbar Shah, Mohamed Abdelnaem Aly, Syed Nazar Imam, Nusaybah Eid Alenazi, Salah Mohamed El Sayed
Hematological disorders are common medical ailments constituting an important cause of morbidity and mortality worldwide, which may be managed efficiently using different prophetic medicine remedies as adjuvants to current therapeutics. Prophetic medicine includes the body of knowledge about medicine that has been derived from the deeds, customs (sunnah), ahadith (sayings), actions, and agreements of Prophet Muhammad, peace be upon him. This review article aims at exploring the magnitude of therapeutic benefits of prophetic medicine remedies as adjuvant treatments to many different types of hematological disorders...
2023: American Journal of Blood Research
Sean E Oldak, Anthony Maristany, William Ventura, Lujain Alhajji, Vanessa L Padilla
Although multiple myeloma (MM) can cause various neurological complications, direct central nervous system (CNS) involvement is exceedingly uncommon and poorly understood. There has been one other reported case in the literature of a patient presenting with psychosis prior to diagnosis of MM. We present a case of a 58-year-old female with no history of psychiatric illness who presented to a behavioral health inpatient unit with paranoid delusions, multisensory hallucinations, and disorganized behavior in the days preceding her MM diagnosis...
August 2023: Curēus
Kazutaka Oda, Ayami Yamaguchi, Naoya Matsumoto, Hirotomo Nakata, Yusuke Higuchi, Kisato Nosaka, Hirofumi Jono, Hideyuki Saito
BACKGROUND: Optimal cefepime dosing is a challenge because of its dose-dependent neurotoxicity. This study aimed to determine individualized cefepime dosing for febrile neutropenia in patients with lymphoma or multiple myeloma. METHODS: This prospective study enrolled 16 patients receiving cefepime at a dose of 2 g every 12 hours. Unbound concentrations were determined at 0.5 hours, 7.2 hours [at the 60% time point of the 12 hours administration interval (C7.2h)], and 11 hours (trough concentration) after the first infusion (rate: 2 g/h)...
September 18, 2023: Therapeutic Drug Monitoring
Ciara L Freeman, Reginald Atkins, Indumathy Varadarajan, Meghan Menges, Jeffrey Edelman, Rachid Baz, Jason Brayer, Omar Castaneda Puglianini, Jose Leonel Ochoa-Bayona, Taiga Nishihori, Kenneth H Shain, Bijal Shah, Dung Tsa Chen, Linda Kelley, Domenico Coppola, Melissa Alsina, Scott Antonia, Claudio Anasetti, Frederick L Locke
PURPOSE: We investigated whether a dendritic cell (DC) vaccine transduced with an adenoviral vector encoded with full-length survivin (Ad-S), with mutations neutralizing its antiapoptotic function, could safely generate an immune response and deepen clinical responses when administered before and after autologous stem cell transplant (ASCT) for multiple myeloma. PATIENTS AND METHODS: This phase I first-in-human trial (NCT02851056) evaluated the safety of DC:Ad-S in newly diagnosed multiple myeloma not having achieved complete response with induction, given 7 to 30 days prior to stem cell collection and 20 to 34 days after ASCT...
September 22, 2023: Clinical Cancer Research
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.